Research ArticleArticle
Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab
Shumpei Yokota, Yasuhiko Itoh, Tomohiro Morio, Naokata Sumitomo, Kaori Daimaru and Seiji Minota
The Journal of Rheumatology February 2015, jrheum.140288; DOI: https://doi.org/10.3899/jrheum.140288
Shumpei Yokota
From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan. Supported by Chugai Pharmaceutical Co. Ltd. S. Yokota has received royalties involving tocilizumab from Chugai. S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Medical and Dental Sciences; N. Sumitomo, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatric Cardiology, Saitama Medical University International Medical Center; K. Daimaru, BS, Chugai Pharmaceutical Co. Ltd.; S. Minota, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Division of Rheumatology and Clinical Immunology, Jichi Medical School. Address correspondence to Dr. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan 236-0004. E-mail: syokota@med.yokohama-cu.ac.jp Accepted for publication December 4, 2014.
Yasuhiko Itoh
From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan. Supported by Chugai Pharmaceutical Co. Ltd. S. Yokota has received royalties involving tocilizumab from Chugai. S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Medical and Dental Sciences; N. Sumitomo, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatric Cardiology, Saitama Medical University International Medical Center; K. Daimaru, BS, Chugai Pharmaceutical Co. Ltd.; S. Minota, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Division of Rheumatology and Clinical Immunology, Jichi Medical School. Address correspondence to Dr. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan 236-0004. E-mail: syokota@med.yokohama-cu.ac.jp Accepted for publication December 4, 2014.
Tomohiro Morio
From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan. Supported by Chugai Pharmaceutical Co. Ltd. S. Yokota has received royalties involving tocilizumab from Chugai. S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Medical and Dental Sciences; N. Sumitomo, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatric Cardiology, Saitama Medical University International Medical Center; K. Daimaru, BS, Chugai Pharmaceutical Co. Ltd.; S. Minota, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Division of Rheumatology and Clinical Immunology, Jichi Medical School. Address correspondence to Dr. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan 236-0004. E-mail: syokota@med.yokohama-cu.ac.jp Accepted for publication December 4, 2014.
Naokata Sumitomo
From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan. Supported by Chugai Pharmaceutical Co. Ltd. S. Yokota has received royalties involving tocilizumab from Chugai. S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Medical and Dental Sciences; N. Sumitomo, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatric Cardiology, Saitama Medical University International Medical Center; K. Daimaru, BS, Chugai Pharmaceutical Co. Ltd.; S. Minota, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Division of Rheumatology and Clinical Immunology, Jichi Medical School. Address correspondence to Dr. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan 236-0004. E-mail: syokota@med.yokohama-cu.ac.jp Accepted for publication December 4, 2014.
Kaori Daimaru
From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan. Supported by Chugai Pharmaceutical Co. Ltd. S. Yokota has received royalties involving tocilizumab from Chugai. S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Medical and Dental Sciences; N. Sumitomo, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatric Cardiology, Saitama Medical University International Medical Center; K. Daimaru, BS, Chugai Pharmaceutical Co. Ltd.; S. Minota, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Division of Rheumatology and Clinical Immunology, Jichi Medical School. Address correspondence to Dr. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan 236-0004. E-mail: syokota@med.yokohama-cu.ac.jp Accepted for publication December 4, 2014.
Seiji Minota
From The Safety Evaluation Committee of Tocilizumab for JIA; Department of Pediatrics, Nippon Medical School; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU) Graduate School of Medical and Dental Sciences; Chugai Pharmaceutical Co. Ltd., Tokyo; Department of Pediatrics, Yokohama City University School of Medicine, Kanagawa; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama; Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan. Supported by Chugai Pharmaceutical Co. Ltd. S. Yokota has received royalties involving tocilizumab from Chugai. S. Yokota, MD, PhD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Yokohama City University School of Medicine; Y. Itoh, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics, Nippon Medical School; T. Morio, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatrics and Developmental Biology, TMDU Graduate School of Medical and Dental Sciences; N. Sumitomo, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Department of Pediatric Cardiology, Saitama Medical University International Medical Center; K. Daimaru, BS, Chugai Pharmaceutical Co. Ltd.; S. Minota, MD, the Safety Evaluation Committee of Tocilizumab for JIA, and the Division of Rheumatology and Clinical Immunology, Jichi Medical School. Address correspondence to Dr. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan 236-0004. E-mail: syokota@med.yokohama-cu.ac.jp Accepted for publication December 4, 2014.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab
Shumpei Yokota, Yasuhiko Itoh, Tomohiro Morio, Naokata Sumitomo, Kaori Daimaru, Seiji Minota
The Journal of Rheumatology Feb 2015, jrheum.140288; DOI: 10.3899/jrheum.140288